Paratek Pharmaceuticals's basic earnings per share (Basic EPS) for the
three
months ended in Jun. 2023 was $-0.25.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.10.
Paratek Pharmaceuticals's EPS without NRI for the
three
months ended in Jun. 2023 was $-0.25.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -1.10.
During the past 3 years, the average EPS without NRIGrowth Rate was 32.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 21.70% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 19.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Paratek Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 81.80% per year. The lowest was -70.30% per year. And the median was 23.80% per year.
Paratek Pharmaceuticals EPS (Basic) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Paratek Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Paratek Pharmaceuticals EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Paratek Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRTK has been successfully added to your 